Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 4/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078325 | 1.00 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23927406 | 0.86 | CA1 (0.49) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078336 | 0.85 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12052203 | 0.81 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28241900 | 0.79 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28241899 | 0.79 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL563862 | 0.79 | HSD11B1 (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL564101 | 0.79 | HSD11B1 (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078330 | 0.78 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL2684262 | 0.78 | LMNA (0.50) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12203938-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220357331-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2022-11-10 | — | — | US | disclosed |
| US-11231424-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200240991-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2020-07-30 | — | — | US | disclosed |
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8841136-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2349335-B1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-8168756-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| EP-2349335-A1 | LEVETIRACETAM IMMUNOASSAYS | ARK Diagnostics, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
| WO-2010048423-A1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12203938-B2 | Levetiracetam immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20220357331-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20200240991-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20120190047-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-11231424-B2 | Levetiracetam immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.